Conditions: Type 2 Diabetes
Keywords: DPP-4 inhibitors HBA1c Incretins
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 568
Healthy volunteers: no

Brief summary:
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Saxagliptin intervention 2: Placebo
Intervention descriptions: intervention 1: 5mg, oral tablet, once daily for 24 weeks intervention 2: oral tablet, once daily for 24 weeks

Protocol document: